DXCMUS#15 US · #24 by MGI
DexCom, Inc.
Analysis last updated Jul 31, 2026. Market data (price, market cap) is the latest available and may differ.
Growth · Value − Threat = Opportunity. Each 0–100. How we score.
Overview
DexCom designs and sells continuous glucose monitoring systems, primarily the G7 sensor and transmitter paired with a mobile app, generating revenue through hardware kit sales and recurring 10-day replacement sensors distributed through pharmacy, DME, and direct channels, a razor-blade model with high consumable attachment and growing international reach. The company also sells Stelo, the first FDA-cleared OTC CGM targeting non-insulin-using adults and now children, extending addressable reach well beyond prescription diabetes care.
Create a free account to read the full thesis and every lens in detail.
The six lenses
DexCom holds approximately 74% of the U. S. CGM market, anchored in clinical accuracy, physician trust, and a recurring-revenue consumable model where sensors are replaced every ten days. …
Learn the principle →At a market capitalization under $50 billion, DexCom faces no meaningful size constraint on its growth opportunity. The existing global CGM market expands at roughly 9% annually, but the larger prize is converting hundreds of millions of non-insulin Type 2 diabetics and wellness-oriented consumers who have no CGM today. …
Learn the principle →Revenue is reaccelerating, with the two most recent quarters printing 13% and 15% year-over-year growth, and full-year 2026 guidance raised to 11-13% growth with gross margins expanding toward 64%. ROIC of 38% is exceptional for a medical device company, and the razor-blade sensor model generates consistent high-quality cash flow at a 28% FCF margin. …
Learn the principle →DexCom carries $601 million of net cash and no material leverage, providing balance sheet capacity for organic investment and bolt-on acquisitions such as NutriSense. Gross margins have expanded to approximately 62–63% as manufacturing efficiencies on the G7 platform compound, while the 28% FCF margin confirms that operating income translates reliably into cash. …
Learn the principle →Kevin Sayer scaled DexCom from roughly $250 million to more than $4. 6 billion in annual revenue over a decade, building the U. S. CGM market leader before transitioning to Executive Chairman in March 2026. …
Learn the principle →The CGM market benefits from secular diabetes prevalence growth and broadening reimbursement, providing a durable industry tailwind. Abbott nonetheless competes aggressively on price internationally and leads globally by volume, creating real margin and share pressure outside the U. S. U. …
Learn the principle →Business profile
Health Care · Health Care Equipment
Management
How the people running it lead, execute, and allocate capital.
Kevin Sayer's decade-long tenure saw DexCom's annual revenue scale from roughly $250 million to more than $4.6 billion, building the U.S. CGM market leader and securing Medicare reimbursement for non-intensive insulin users. The company launched multiple sensor generations including the G6, G7, and G7 15-Day, pioneered the first OTC CGM in Stelo (2024), and invested $75 million in Oura to secure the only CGM-smart-ring integration. New CEO Jake Leach, a 21-year company veteran and former CTO, assumed leadership in January 2026 with Kevin Sayer remaining as Executive Chairman.
Scorecard
- Moat63Moderate
- Runway83Strong
- Growth Engine73Strong
- Financials79Strong
- Management70Strong
- Risks59Moderate
Six lenses, each 0–100 and rated Strong / Moderate / Weak; the swing factor most decides the outcome. What each lens means.
Fundamentals
How it makes money
Revenue by segment, sized by share. Click a segment for the full detail.
Valuation
Live market multiples, plus a separate estimate of what the business is worth. Information only, not a price target.
Forward Multiple. 26x FY2027 FCF of ~$1.6B, a multiple warranted by 13-15% growth, 38% ROIC, 28% FCF margin, net cash balance sheet, and multiple underpenetrated expansion vectors; discounted ~1.5 years at 10%
ConfidenceHigh72/100What's priced in: The market looks too cautious.
The market is pricing in only 6% annual revenue growth for the next decade, yet DexCom is actively delivering 13-15% growth with expanding FCF margins and several underpenetrated vectors — Type 2 non-insulin CGM reimbursement, Stelo OTC adoption, and the international G7 15-Day rollout — still in early innings. At 19x FCF for a razor-blade medtech compounding at 38% ROIC with a net cash balance sheet and durable domestic moat, the current price embeds an unduly pessimistic growth assumption; a fair 26x forward FCF multiple implies a market cap closer to $40B, roughly 47% above where the stock trades.
Competes with
Covered names link to their analysis; greyed names are private or outside our universe.
Scores over time
Each nightly run adds a point; trends build as history accumulates.
Think our analysis of DexCom, Inc. missed the mark? We are always trying to improve Multibagger.